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7.4, p = 0.0065) among groups Vioxx, Cox2-Vioxx and Others
in the adverse events rates of 5.84%, 5.00% and 3.83% respec-
tively. Further Logistic regression anlaysis revealed that Vioxx
and Cox2-Vioxx patients experienced higher events rates (group
Vioxx vs. Others: OR = 1.218, 95%CI = 0.905–1.640; group
Cox2-Vioxx vs. Others OR = 1.13, 95%CI = 0.834–1.532) with
inﬂuencing factors adjusted, gender (male OR = 1.555, 95%CI
= 1.190–2.031), age (OR = 1.080, 95%CI = 1.063–1.097) and
comorbidities. CONCLUSIONS: The study demonstrated that
Vioxx before withdrawn from market had highest heart
attack/stroke events as compared to other Cox2 drugs or drug
class. The other Cox2 drugs, Celebrex and Bextra, had higher
adverse events than other painkiller classes such as NSAIDs. The
follow up study with extended data is expected to conﬁrm the
ﬁnding.
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OBJECTIVES: Rituximab (RTX; MabThera), a unique B-cell
therapy, is a new option for rheumatoid arthritis (RA) patients
who respond inadequately to anti-TNF therapies. This analysis
evaluated the cost-effectiveness of introducing RTX from the
perspective of the UK NHS. METHODS: The model simulated,
over a patient’s expected lifetime, the real-life treatment sequence
for 10,000 RA patients who respond inadequately to one anti-
TNF therapy. Baseline characteristics were aligned with the
REFLEX study. Clinical outcomes were based upon ACR
response rates (adjusted for different study populations) and
complemented with observational data. The model estimated the
incremental cost per quality-adjusted life-year (QALY) of a typi-
cal treatment sequence containing RTX compared to the same
treatment sequence without RTX. Average time-on-treatment for
biological agents was up to 4.25 years. QALYs were mapped
from a disease severity measure (HAQ score). All direct NHS
costs were included in the model, as well as those related to
disease progression and palliative care. Costs and beneﬁts were
discounted at 3.5%. RESULTS: The annual average drug cost
for each drug in the model was BRP5834 for RTX + MTX (infu-
sion of 2 ¥ 1 gram every 9 months), BRP10,138 for adalimumab,
BRP10,279 for etanercept, and BRP8542 for inﬂiximab. The
model estimated that when added to an existing treatment
sequence, RTX would lead to a gain of 0.526 QALYs at an ad-
ditional cost of BRP7417 per patient. The incremental cost-
effectiveness ratio (ICER) of RTX was consequently BRP14,122.
When RTX replaced adalimumab as a second-line biologic
DMARD, RTX + MTX was associated with a cost-saving of
BRP13,000 over a patient’s lifetime. CONCLUSIONS: RTX as
a treatment option for RA patients who fail to respond to anti-
TNF therapy is a cost effective treatment option from the per-
spective of the UK NHS. The resulting cost effectiveness ratio
falls well below commonly accepted thresholds within the UK.
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OBJECTIVES: Rituximab (RTX; MabThera), a unique selective
B-cell therapy, represents a new option for patients with rheuma-
toid arthritis (RA) who have responded inadequately to anti-
TNF therapies. We analysed the cost-effectiveness of RTX from
a German societal perspective. METHODS: We developed a
model using published ACR response rates for RTX and current
treatment choices (adjusted for study population differences),
plus available observational data, German registry resource-
utilisation data and baseline patient characteristics from the
REFLEX study. We modelled real-life treatment for 10,000 RA
patients who had responded inadequately to one anti-TNF
therapy over the patient’s lifetime, assuming an average treat-
ment duration for biological therapy (in combination with
methotrexate) of up to 4.25 years. QALYs were mapped from a
disease severity measure (HAQ score). Relevant costs (2004–5
Euros [€]) included those related to drug (including administra-
tion and monitoring) and indirect costs through reduced pro-
ductivity. Costs and beneﬁts were discounted at 3.5% per year.
We assessed either adding RTX or using it instead of adali-
mumab. RESULTS: Annual average drug therapy costs were
€10,208 for RTX + MTX, €22,574 for adalimumab, €22,630 for
etanercept, and €13,484 for inﬂiximab. RTX as an additional
treatment gave an additional 0.531 QALYs at an incremental
total direct medical cost of €16,527 over the patient’s lifetime.
With an incremental QALY of 0.665 this would result in an
incremental direct medical cost of €24,844 per QALY. The cor-
responding ICERs were €25,985 and €17,058 per QALY gained.
Using RTX as an alternative to adalimumab would produce a
small incremental QALY gain, together with lifetime cost-savings
of €23,143. CONCLUSIONS: In Germany, the incremental cost
of adding RTX to options for RA-patients who respond inade-
quately to anti-TNF therapy is favourable using commonly
accepted cost-effectiveness thresholds. As a replacement for a
currently used drug in second-line biologic DMARD, RTX could
lower average annual treatment costs.
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OBJECTIVES: To explore inﬂuences of patient and clinical char-
acteristics on the cost-effectiveness of selective COX-2 inhibitors
and traditional NSAIDs in patients with osteoarthritis.
METHODS: A published cost-effectiveness model (Arthritis
Rheum 2003;49:283–92) was modiﬁed to incorporate important
clinical characteristics that can inﬂuence the risk of gastroin-
testinal (GI) complications such as age, gender, history of GI
bleed, and low-dose aspirin intake. The modiﬁed model used
data from a large clinical trial (TARGET) to estimate base GI
